SHERIDAN, WYOMING – July 25, 2025 – Roche has announced topline results from two pivotal clinical trials evaluating astegolimab for chronic obstructive pulmonary disease (COPD), highlighting a complex development path for the investigational monoclonal antibody. The phase IIb ALIENTO trial met its primary endpoint, while the phase III ARNASA trial did not, despite both showing numerical reductions in exacerbation rates.

Phase IIb ALIENTO Achieves Statistically Significant Reduction in Exacerbations

SHERIDAN, WYOMING – July 22, 2025 – Globus Medical, Inc. has announced a significant leadership transition, positioning its executive team for continued strategic growth in the musculoskeletal technology sector. Effective July 18, 2025, Keith Pfeil assumed the role of President and Chief Executive Officer, succeeding Daniel Scavilla, who stepped down to pursue another opportunity. Additionally, Kyle Kline was appointed Senior Vice President and Chief Financial Officer.

Leadership Shifts Focused on Strategic Growth

SHERIDAN, WYOMING – July 22, 2025 – Globus Medical, Inc. has scheduled the announcement of its financial results for the second quarter ended June 30, 2025, for Thursday, August 7, 2025, after market close. The musculoskeletal technology leader will publish the earnings release on its investor relations website at www.investors.globusmedical.com.

Investor Call Scheduled for August 7

SHERIDAN, WYOMING – July 22, 2025 – Globus Medical, Inc. has announced the expansion of its Excelsius™ navigation capabilities with the introduction of DuraPro™, a next-generation oscillating system designed to enhance surgical precision while safeguarding delicate tissue. As part of the company’s Power Portfolio, DuraPro™ aims to optimize procedural workflows by combining advanced oscillating technology with integrated navigation.

Advancing the High-Speed Drill Market with Next-Generation Oscillation

SHERIDAN, WYOMING – July 22, 2025 – Globus Medical, Inc. (NYSE: GMED), a global leader in musculoskeletal solutions, today announced a significant strategic initiative with the authorization of a share repurchase program of up to $500 million of the company’s outstanding common stock. The move underscores Globus Medical’s confidence in its long-term business fundamentals and commitment to delivering sustained value for shareholders.

Strategic Response to Market Valuation Trends